Core Viewpoint - The company is undergoing a board restructuring process, including the nomination of candidates for the sixth board of directors and the establishment of new governance policies to enhance operational standards and corporate governance [3][4][20]. Group 1: Board Restructuring - The fifth board of directors has completed its term, and the company plans to elect a new sixth board consisting of nine members, including three independent directors and one employee representative [3][5]. - The board candidates have been nominated and will be subject to approval at the upcoming extraordinary general meeting [4][5]. - The election will utilize a cumulative voting system, and the new board's term will commence upon approval by the shareholders [5]. Group 2: Governance Policy Updates - The company is revising several governance policies, including the management of resignations for directors and senior management, to align with legal requirements and improve governance structures [2]. - The revised policies will also be presented for approval at the extraordinary general meeting [2]. Group 3: Candidate Qualifications - All nominated candidates meet the legal and regulatory requirements for board membership, with no disqualifications or conflicts of interest reported [6][10][21]. - The independent director candidates have completed the necessary training and have been approved by the Shanghai Stock Exchange [6][16]. Group 4: Employee Representative Election - The employee representative director has been elected by the employee representative assembly and will join the newly elected board [20][21].
陕西康惠制药股份有限公司 关于董事会换届选举的公告